Logo of Paradigm Biopharmaceuticals (ASX:PAR)Latest Paradigm Biopharmaceuticals (ASX:PAR) News

Page 1
Page 1 of 5

Independent review revives Paradigm’s case for a new iPPS trial outside the US

An independent interim analysis has confirmed statistically significant iPPS benefits in Paradigm’s rest-of-world knee osteoarthritis cohort, giving the company a possible route to continue development despite the overall trial failing its futility test. Any new trial remains subject to funding, creditor approval and regulatory discussions.
Ada Torres
19 Nov 2026

Market Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Explorers led the strongest gains, while biotech, payments and gold producers suffered the biggest falls. Takeover bids, project funding and trial results drove sharp moves across the market.

Resources stayed busy, but investors punished companies with weak cash positions, delayed approvals or disappointing operating updates.
Logan Eniac
31 Oct 2026

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Paradigm trial fails futility test as administration enters its next phase

Paradigm Biopharmaceuticals’ pivotal knee osteoarthritis trial fell below its pre-specified continuation threshold, leaving the ASX-listed biotech in voluntary administration with A$4.33 million in cash. Administrators now have up to three months to assess restructuring options, clinical data and the company’s future.
Victor Sage
30 Oct 2026

Paradigm creditors get three more months before the next insolvency decision

Paradigm Biopharmaceuticals has secured court approval to delay its second creditors meeting until 27 January 2027, giving administrators more time to resolve outstanding matters. The meeting and administrators’ report could still arrive earlier, potentially within weeks.
Victor Sage
28 Oct 2026

Market Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Prominence Energy doubled as hydrogen speculation drove the week’s biggest move, while takeover news lifted RAS Technology and Cleanaway.
Zip Co and several resource developers fell as investors weighed costs, capital needs and delivery risks.
Logan Eniac
24 Oct 2026

Healthcare Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Healthcare shares ended a difficult week with funding worries weighing on smaller companies, even as several groups reported stronger sales or clinical progress. Starpharma, Hydration Pharmaceuticals and Saluda were among the largest fallers, while Recce, Zoono and Genetic Signatures posted gains.
Logan Eniac
24 Oct 2026

Paradigm seeks court time to avoid liquidation as recapitalisation proposals remain unresolved

Paradigm’s administrators have asked the Supreme Court of Western Australia for up to three more months to assess sale and recapitalisation proposals. Without the extension, they say they would have no alternative but to recommend winding up the biotech.
Ada Torres
23 Oct 2026

Market Wrap - Week 42 (12 Oct -> 16 Oct) 2026

Small-cap shares swung widely as exploration results, takeover bids and funding needs drove the week’s biggest moves.
Kaoko plunged while PARKD rallied, showing how quickly thinly traded stocks can change direction.
Logan Eniac
17 Oct 2026

Healthcare Wrap - Week 42 (12 Oct -> 16 Oct) 2026

Healthcare shares swung between sharp selling and early commercial progress this week, with EBR Systems falling 40.43% while Firebrick rose 13.79%.
Sales growth, clinical decisions and limited cash reserves remained the key tests for small healthcare companies.
Logan Eniac
17 Oct 2026

Paradigm finds regional iPPS benefit, but administration leaves Phase 3 future uncertain

Paradigm has reported a strong pain and function signal for iPPS outside the US, including a 1.105-point advantage over placebo at Day 112. The result does not revive the halted Phase 3 trial, with the company under administration and a potential funding proposal still unreceived.
Ada Torres
15 Oct 2026

Market Wrap - Week 40 (28 Sept -> 2 Oct) 2026

Small-cap shares delivered the week’s biggest moves, led by Mamba’s exploration funding and Cettire’s rebound. Clinical failures, cash shortages and delayed projects kept the broader market cautious.
Logan Eniac
3 Oct 2026